FDA Approval Sought for Naxitamab in Neuroblastoma
Pharma & biotech2020-04-04
29 Views
A Biologics License Application has been filed with the FDA for naxitamab for the treatment of patients with relapsed/refractory high-risk neuroblastoma.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Breaking News: Crown Equity Holdings, Inc. Announces Letter of Intent with BioHarvest Naturals Corp.
